This is a preview of subscription content, log in via an institution to check access.
Notes
Management of Myocardial Injury after Non-Cardiac Surgery
Reference
Lamy A, et al. The Cost Implications of Dabigatran in Patients with Myocardial Injury After Non-Cardiac Surgery. American Journal of Cardiovascular Drugs : 26 Jul 2021. Available from: URL: http://doi.org/10.1007/s40256-021-00489-3
Rights and permissions
About this article
Cite this article
Dabigatran appears to be cost neutral for managing post-surgical myocardial injury. PharmacoEcon Outcomes News 884, 12 (2021). https://doi.org/10.1007/s40274-021-7919-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7919-1